文献速递产科母胎医学

胎盘生长因子检测指导晚发型早产子痫前期管理:多中心随机对照试验

Placental growth factor testing in the management of late preterm preeclampsia without severe features: a multicenter, randomized, controlled trial.
PubMed 文献 · Am J Obstet Gynecol · 2021-04-03

该多中心随机对照试验在西班牙7个产科单位纳入178例34至36+6周晚发型早产子痫前期单胎孕妇,比较基于胎盘生长因子水平的选择性计划分娩与常规期待管理。

要点

  • 基于胎盘生长因子水平的算法可降低晚发型早产子痫前期进展为重度特征的风险。
  • 该策略未增加新生儿发病率,但研究未达所需样本量。
  • 应与患者讨论分娩时机权衡以支持共享决策。

核心结论

  • 基于胎盘生长因子水平的算法可降低晚发型早产子痫前期孕妇进展为重度子痫前期的比例,并减少母体并发症,且不加重新生儿结局。

研究设计与样本

  • 平行组、开放标签、多中心随机对照试验,在西班牙7个产科单位进行,纳入34至36+6周晚发型早产子痫前期单胎孕妇,共招募178例,揭示组88例, concealed组90例,按意向性分析。

关键数值与推荐

  • 共同主要母体结局为进展为重度子痫前期,共同主要新生儿结局为出院时发病率,非劣效界值为10%的发病率差异。

临床怎么用

  • 对于晚发型早产子痫前期孕妇,可依据胎盘生长因子水平评估分娩时机,并与患者讨论母胎权衡以共享决策。

局限性

  • 数据分析在完成所需样本量之前进行。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In women with late preterm preeclampsia, the optimal time for delivery remains a controversial topic, because of the fine balance between the maternal benefits from early delivery and the risks for prematurity. It remains challenging to define prognostic markers to identify women at highest risk for complications, in which case a selective, planned delivery may reduce the adverse maternal and perinatal outcomes. OBJECTIVE: This trial aimed to determine whether using an algorithm based on the maternal levels of placental growth factor in women with late preterm preeclampsia to evaluate the best time for delivery reduced the progression to preeclampsia with severe features without increasing the adverse perinatal outcomes. STUDY DESIGN: This parallel-group, open-label, multicenter, randomized controlled trial was conducted at 7 maternity units across Spain. We compared selective planned deliveries based on maternal levels of placental growth factor at admission (revealed group) and expectant management under usual care (concealed group) with individual randomization in singleton pregnancies with late preterm preeclampsia from 34 to 36+6 weeks' gestation. The coprimary maternal outcome was the progression to preeclampsia with severe features. The coprimary neonatal outcome was morbidity at infant hospital discharge with a noninferiority hypothesis (noninferiority margin of 10% difference in incidence). Analyses were conducted according to intention-to-treat. RESULTS: Between January 1, 2016, and December 31, 2019, 178 women were recruited. Of those women, 88 were assigned to the revealed group and 90 were assigned to the concealed group. The data analysis was performed before the completion of the required sample size. The proportion of women with progression to preeclampsia with severe features was significantly lower in the revealed group than in the concealed group (adjusted relative risk, 0.5; 95% confidence interval, 0.33-0.76; P=.001). The proportion of infants with neonatal morbidity was not significantly different between groups (adjusted relative risk, 0.77; 95% confidence interval, 0.39-1.53; P=.45). CONCLUSION: There is evidence to suggest that the use of an algorithm based on placental growth factor levels in women with late preterm preeclampsia leads to a lower rate of progression to preeclampsia with severe features and reduces maternal complications without worsening the neonatal outcomes. This trade-off should be discussed with women with late preterm preeclampsia to allow shared decision making about the timing of delivery.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Peguero A, Herraiz I, Perales A, et al. Placental growth factor testing in the management of late preterm preeclampsia without severe features: a multicenter, randomized, controlled trial. Am J Obstet Gynecol. 2021. PMID: 33823150. doi:10.1016/j.ajog.2021.03.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。